# Saide Dikang

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/saide-dikang

- Industry: Materials
- Headquarters: Hangzhou, China
- Latest round: Series B (Feb 18, 2025)
- Investors on record: 2

## About

Established in 2019 and based in Hangzhou, China, Saide Dikang is a medical restorative material research and development company. The company has R&D centers and production bases in both China and the United States. In February 2025, it closed a series B funding from returning investor Lapam Capital and new investor Samuel Guo.

The company’s main business is to develop advanced wound management solutions and innovative repair products for acute and chronic wounds. The company’s self-developed product is the PermeaDerm, a biosynthetic membrane repair material from its proprietary technology platform. Its products are applied in multiple fields, including wound repair, surgery, orthopedic trauma, neurology, and cardiovascular.

Saide Dikang generates revenue by supplying its wound management products to medical institutions globally and through technology-based cooperation and licensing agreements.

The company will use the series B funding for the research and development and clinical research of innovative repair products for acute and chronic wounds and expand human resources.

## Funding rounds

- Series B, Feb 18, 2025 — Lapam Capital, Shanghai Healthcare Capital

## Investors

- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series B
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series B